Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of BIA 3-202 in Healthy Volunteers
NCT02763787Phase 1Completed
- Sponsor
- BIAL
- Start
- Apr 2000
- Primary completion
- Jun 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nebicapone in Parkinson's disease (PD) (9 arms), sponsored by BIAL. Primary endpoints: Maximum observed plasma concentration, Time of maximum observed concentration and 2 more. Started Apr 2000; status: completed.
02
Drugs
nebicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02763787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02763787.